Valganciclovir for Congenital Cytomegalovirus
Authors:
- David W KimberlinDKDavid W Kimberlin
- Inmaculada AbanIAInmaculada Aban
- Edward P AcostaEAEdward P Acosta
- 18 June 2015
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 372 (25) , 2462-2463
Abstract
To the Editor: In the treatment of congenital cytomegalovirus infection, administration of valganciclovir therapy for 6 months is four times as long as administration for 6 weeks. In this regard, Kimberlin et al. (March 5 issue)1 do not underscore an important finding of their study; in fact, a comparison of the trends of the viral load in whole blood in the two study groups shows that a significant difference (in favor of the patients who received valganciclovir for 6 months) was evident only from day 56 until day 84, whereas no difference was detectable from 4 to 6 months of . . .Keywords
This publication has 5 references indexed in Scilit:
- Valganciclovir for Symptomatic Congenital Cytomegalovirus DiseaseNew England Journal of Medicine, 2015
- Clinically targeted screening for congenital CMV - potential for integration into the National Hearing Screening ProgrammeActa Paediatrica, 2013
- Congenital cytomegalovirus infection: patterns of fetal brain damageClinical Microbiology and Infection, 2012
- Congenital Cytomegalovirus Infection: Association between Virus Burden in Infancy and Hearing LossThe Journal of Pediatrics, 2005
- Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trialThe Journal of Pediatrics, 2003